Alzamend Neuro, Inc.
ALZN
$2.15
-$0.05-2.27%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.83M | -6.24M | -4.51M | -4.23M | -5.90M |
| Total Depreciation and Amortization | 80.80K | 65.80K | 50.80K | 50.80K | 50.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 237.00K | 286.80K | 334.50K | 335.20K | 440.50K |
| Change in Net Operating Assets | -135.60K | -1.98M | -2.44M | -3.47M | -2.50M |
| Cash from Operations | -5.65M | -7.88M | -6.57M | -7.31M | -7.91M |
| Capital Expenditure | -210.00K | -210.00K | -300.00K | -90.00K | -90.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -210.00K | -210.00K | -300.00K | -90.00K | -90.00K |
| Total Debt Issued | -- | -- | -- | 300.00K | 300.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.53M | 2.70M | 2.70M | 2.13M | 2.41M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 4.68M | 9.81M | 7.74M | 8.04M | 9.19M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.21M | 12.51M | 10.44M | 10.47M | 11.90M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 356.40K | 4.43M | 3.57M | 3.08M | 3.89M |